BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26842910)

  • 21. 7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer.
    Zhang E; Liu J; Shi L; Guo X; Liang Z; Zuo J; Xu H; Wang H; Shu X; Huang S; Zhang S; Kang X; Zhen Y
    Life Sci; 2019 Dec; 238():116938. PubMed ID: 31593704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
    Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
    J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
    Wu Y; Yao Y; Yun Y; Wang M; Zhu R
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31409725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway.
    Huang Q; Wu YY; Xing SJ; Yu ZW
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5285-5292. PubMed ID: 31298380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells.
    Shi X; Valizadeh A; Mir SM; Asemi Z; Karimian A; Majidina M; Safa A; Yosefi B
    Eur J Pharmacol; 2020 Aug; 880():173138. PubMed ID: 32416187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [miR-34a may regulate sensitivity of breast cancer cells to adriamycin via targeting Notch1].
    Li X; Zhao J; Tang J
    Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):892-6. PubMed ID: 25623761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction to: MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1).
    Zhao L; Wang Y; Jiang L; He M; Bai X; Yu L; Wei M
    J Exp Clin Cancer Res; 2022 Mar; 41(1):94. PubMed ID: 35279218
    [No Abstract]   [Full Text] [Related]  

  • 28. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
    Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
    Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA KCNQ1OT1 contributes to the progression and chemoresistance in acute myeloid leukemia by modulating Tspan3 through suppressing miR-193a-3p.
    Sun H; Sun Y; Chen Q; Xu Z
    Life Sci; 2020 Jan; 241():117161. PubMed ID: 31837329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of different heating methods combined with neferine on the expressions of γH2AX and mdr-1/P-gp in MCF-7/Adr breast cancer cells].
    Huang C; Cao P; Xie Z; Zhu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Apr; 36(4):317-22. PubMed ID: 21566283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
    Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
    Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin.
    Han B; Huang J; Han Y; Hao J; Wu X; Song H; Chen X; Shen Q; Dong X; Pang H; Cai L
    Int J Biol Macromol; 2019 Mar; 125():544-556. PubMed ID: 30537505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca
    Sun Y; Wang C; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Peng J; Liu K
    J Cell Physiol; 2018 Apr; 233(4):3066-3079. PubMed ID: 28681913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
    Zhang J; Zhang HD; Yao YF; Zhong SL; Zhao JH; Tang JH
    Cell Physiol Biochem; 2015; 36(6):2274-86. PubMed ID: 26279432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-treatment With Aripiprazole and Vincristine Sensitizes P-Glycoprotein-Overexpressing Drug-resistant MCF-7/ADR Breast Cancer Cells.
    Shin JK; Kim HS; Yoon S
    Anticancer Res; 2024 Mar; 44(3):1051-1062. PubMed ID: 38423668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2.
    Zeng H; Wang L; Wang J; Chen T; Li H; Zhang K; Chen J; Zhen S; Tuluhong D; Li J; Wang S
    Arch Biochem Biophys; 2018 Aug; 651():52-60. PubMed ID: 29802821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.
    Kanagasabai R; Krishnamurthy K; Druhan LJ; Ilangovan G
    J Biol Chem; 2011 Sep; 286(38):33289-300. PubMed ID: 21784846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
    Sun FD; Wang PC; Luan RL; Zou SH; Du X
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
    Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
    Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
    Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
    Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.